1260 Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

✍ Scribed by P. Schöffski; J.Y. Blay; J. DeGreve; E. Brain; J.P. Machiels; J.C. Soria; S. Sleijfer; G. Munzert; J. Rapion; D. Lacombe

• Book ID: 119600233
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 67 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)70472-0